Breaking Finance News

BidaskClub upgraded Acorda Therapeutics Inc (NASDAQ:ACOR) to Strong-Buy in a report released today.

BidaskClub has upgraded Acorda Therapeutics Inc (NASDAQ:ACOR) to Strong-Buy in a report released on 7/7/2017.

Yesterday Acorda Therapeutics Inc (NASDAQ:ACOR) traded 4.40% higher at $20.85. The company’s 50-day moving average is $20.82 and its 200-day moving average is $20.34. The last stock close price is up 4.96% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 432,186 shares of the stock were exchanged, down from an average trading volume of 816,055

See Chart Below

Acorda Therapeutics Inc (NASDAQ:ACOR)

Acorda Therapeutics Inc has a 52 week low of $13.60 and a 52 week high of $33.00 The company’s market cap is currently $0.

In addition to BidaskClub reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $47.20 with 1 firm rating the stock a strong buy, 3 firms rating the stock a buy, 4 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Acorda Therapeutics Inc (NASDAQ:ACOR)

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *